Media library

EMCDDA webinar: workplaces and drugs, issues and challenges for the future, 28 April 2022 12.00-13-30 CET

EMCDDA webinar: Workplaces and drugs – issues and challenges for the future

May 2022
photo of the EU Drug Markets press conference room. Mr Alexis Goosdeel, Ms Catherine De Bolle and Ms Kathryn Robertson seating

Recording of the EU Drug Markets: cocaine and methamphetamine press conference

May 2022
photo of hands rolling a cannabis cigarette. Women and Drugs in Europe: why gender matters

EMCDDA webinar: Women and drugs in Europe — why gender matters

April 2022

Main behavioural techniques used in prevention interventions in high-risk neighbourhoods: evidence of effectiveness, 2019

March 2022
Availability of awareness-raising responses in the workplace in Europe ranges from Finland (58.3%) to Estonia (20.9%) with an EU27 average at 36.2%.

Availability of awareness-raising responses in the workplace to prevent substance use (e.g. smoking, alcohol or drugs)

March 2022

Number of countries reporting availability of interventions targeting people who use drugs in prison in Europe, 2019

March 2022

Interventions in high-risk neighbourhoods: provision in European countries, 2019

March 2022
screenshot of hair sample video: hand with gloves cutting hair sample from a doll's head

Demonstration of hair drug testing sample collection

March 2022
Video thumbnail showing EMCDDA Director Alexis Goosdeel

EMCDDA and the changing face of Europe's drugs problem

February 2022

Infographic: Has the COVID-19 pandemic had any impact on your drug use?

January 2022

Infographic: Participants by country (European Web Survey 2021)

January 2022
Countries in the west of Europe are more likely to provide take-home naloxone than in the east of Europe

Infographic. Availability of take-home naloxone programmes in Europe

December 2021
photo of people passing in a hospital corridor with text emcdda webinar wednesday, 8 december 2021, 13.00-14.00 cet brussels time, drug related deaths in europe, current challenges and implications for responses

EMCDDA webinar: Drug-related deaths in Europe, current challenges and implications for responses

December 2021
Shows people looking at a display of various drug-related items on a table

European Commissioner Johansson and EMCDDA Director Goosdeel visit Belgian National Institute of Criminalistics and Criminology

December 2021
European Commissioner Johansson and EMCDDA Director Goosdeel listening to someone

European Commissioner Johansson and EMCDDA Director Goosdeel visit Belgian National Institute of Criminalistics and Criminology

December 2021
Group photo in front of building

European Commissioner Johansson and EMCDDA Director Goosdeel visit Belgian National Institute of Criminalistics and Criminology

December 2021
Video screenshot of EU4MD video

EMCDDA beyond EU borders: spotlight on countries neighbouring the EU (EU4MD)

November 2021
Video thumbnail of the video on IPA

EMCDDA beyond EU borders: spotlight on pre-accession partners (IPA)

November 2021
Screenshot from the webinar on cannabis control approaches

EMCDDA webinar: Cannabis control approaches across Europe

November 2021
Some characteristics of clients entering treatment for opioids in Europe. Most are men, self-referred, in outpatient setttings and in stable accomodation. Herion is the primary drug and injection is not the primary route of administration.

Infographic: clients entering treatment for opioids in Europe

October 2021
Screenshot of the EMCDDA webinar on health and social responses to cannabis showing chair person Jane Mounteney and a slide presenting the European Responses Guide

EMCDDA Webinar: Health and social responses to cannabis problems in Europe — time for a paradigm shift?

October 2021
only two countries in Europe have achieved the OAT and syringe targets defined by the World Health Organisation

Infographic. Number of sterile syringes distributed per person who injects drugs and proportion of high-risk opioid users in opioid agonist treatment (OAT)

July 2021
Screenshot of a presentation from the EMCDDA webinar on prison and drugs

EMCDDA webinar: Prison and drugs in Europe: current and future challenges

June 2021
Video Screenshot of EMCDDA Director Alexis Goosdeel

Spotlight: Impact of COVID-19 on EMCDDA activities

June 2021
Video screenshot of the press conference on occasion of the European Drug Report launch with Kathryn Robertson, Media relations, and EMCDDA Director Alexis Goosdeel seated in the launch studio.

Video: Launch of the 2021 European Drug Report: Online media event

June 2021
Screenshot of a presentation from the EMCDDA webinar on the Summer School

EMCDDA Webinar: EMCDDA drugs schools and the next generation of drug professionals

June 2021
Video Screenshot of Commissioner Ylva Johansson

Video: Launch of the 2021 European Drug Report: speech by Commissioner Ylva Johansson

June 2021
Image of a port with container ships seen from top with the text 'A record 213 tonnes of cocaine were seized in 2019'

Video: European Drug Report 2021 — highlights

June 2021
Video Screenshot of Chair of the EMCDDA Management Board Laura d’Arrigo

Video: Launch of the 2021 European Drug Report: speech by the Chair of the EMCDDA Management Board Laura d’Arrigo

June 2021
status for benzodiazepines.1960s: Librium, first to market. 1984 32 benzodiazepines. 1990 Midazolam. 1995 Flunitrazepam. 2016 Phenazepam. 2020 Etizolam and Flualprazolam

Timeline of the international control status of benzodiazepines

June 2021
Loading